InnovAge Holding Corp. (INNV) on Q3 2022 Results - Earnings Call Transcript
Operator: Good day and thank you for standing by and welcome to the InnovAge Fiscal Third Quarter 2022 Earnings Conference Call. I would now like to hand the conference over to your host today, Ryan Kubota, Director of Investor Relations. You may begin.
Ryan Kubota: Thank you, operator. Good afternoon and thank you all for joining InnovAge’s fiscal 2022 third quarter earnings call. With me today is Patrick Blair, President and CEO; and Barbara Gutierrez, CFO. Dr. Melissa Welch, Chief Medical Officer, will also be joining the Q&A portion of the call. Today, after the market closed, we issued a press release containing detailed information on our quarterly results. You may access the release on our company website, innovage.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, May 10, 2022, and have not been updated subsequent to this call. During this call, we will refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our third quarter 2022 press release, which is posted on the Investor Relations section of our website. We will also be making forward-looking statements, including statements related to our remediation measures, including scaling our capabilities as a provider, expanding our payer capabilities and strengthening our enterprise functions, future growth prospects, the status of current and future regulatory actions and other expectations. Listeners are cautioned that all of our forward-looking statements involve certain assumptions and are inherently subject to risks and uncertainties that can cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in our Form 10 annual report for fiscal year 2021 and our subsequent reports filed with the SEC, including our quarterly report on Form 10-Q for our fiscal third quarter 2022. After the completion of our prepared remarks, we will open the call for questions. I will now turn the call over to our President and CEO, Patrick Blair. Patrick?
Patrick Blair: Good morning. Thank you, Ryan, and thank you all for joining us today. Before jumping in, I’d like to again express my gratitude to our InnovAge employees who put our participants at the core of what we do every day, and for their selfless contributions during a difficult time; our federal and state partners for their partnership and support as we work through the audits; and to our shareholders for their continued interest in the company. There is a lot to cover today. So our prepared remarks will be a bit longer than usual. It’s a challenging period for InnovAge, and this quarter’s results reflect the significant transformation we’re undertaking. I’m confident we’ll manage our situation in the right way, and we’re optimistic about the company’s future, both in terms of the markets we serve and the solutions we offer. While the current sanctions represent a major challenge, I’m generally excited about the market opportunity, the foothold we have in important markets, our incredible PACE clinical expertise and the amazing employees who are proud to work at InnovAge. I have been encouraged by our progress over the last 90 days. And while it’s certainly requiring a lot from them, it’s clear that our employees have the motivation and ability to overcome the challenges we’re facing. Their efforts are frankly inspiring, and the improvements, while still early, are becoming visible. As you know, we are currently under sanction in our Sacramento Center as well as our 6 centers in the state of Colorado. As a result of these sanctions, we’re currently unable to grow our census in these markets. We’re following the lead of CMS and state government partners, and working with them to ensure they are satisfied completely with the work we are doing to address the audit findings. The regulators determine timeline for the audit process, and we’re doing everything we can to satisfy the requirements to lift the sanctions. I will provide a detailed overview for each of our markets, but suffice to say these learnings through a difficult period will make this organization a more disciplined and compliant organization in the long-term. Today’s discussion is going to focus on near-term operational execution and mid- to long-term capability development. These are the core drivers of horizons necessary to comprehensively remediate the deficiencies identified in our recent audits. And equally important, they are the foundational building blocks to ensure we’re well positioned for scalable, sustainable long-term growth. As a leadership team, an organization, and with the full commitment of our board, we are defying success and holding ourselves accountable across both horizons. My objective today is to delineate and to put into context the full portfolio of actions we’re taking. On our last call – I have been in the CEO seat for 30 days. It’s now been a little over 4 months. So I’m going to begin with some current reflections and follow that with updates on the critical work underway in the progress to-date along three dimensions of remediation and transformation, which encompasses what we are calling One InnovAge, the status in each of our market with our regulators, perspectives on the quarter and concluding thoughts. I’ll then turn it over to Barbara to provide a detailed financial overview before we open it up for questions. To help bridge from our last call, I’d like to anchor back to some observations shared in February as I was first immersing myself in the audit results and business operations. I committed then that my immediate highest priority was to address the audit findings and to restore our regulators’ trust in InnovAge. Now with an additional 90 days under my belt, I’m in a much better position to provide additional granularity on what must change. I’ve spoken with employees, government partners and reached out via personalized letter to all 6,800 participants asking them for feedback on how we’re doing. This has led to not only a more detailed understanding of identified audit deficiencies and associated root causes, but also the specific transformational actions required to support the lifting of sanctions. The PACE program is unique, and the core program design requires both provider and payer competencies to participate. We’re assuming both full underwriting risk for our participants and managing the delivery of care for a very high acuity population. I want to distinguish between the provider and payer attributes as the capabilities to be best-in-class differ. And in the case of InnovAge, each dimension needs to be robust and seamlessly orchestrated to be successful at a national scale. On our last call, I communicated my belief that InnovAge possesses a sturdy foundation and tremendous potential. I still believe this. But now with more time in the business, it’s also clear that to enable a consistent, scalable platform, our capabilities as a provider and a payer, respectively, require enhancements and need to evolve. I also believe that payer capability enhancements represent incremental opportunity, and I will share more detail on our plans to execute against this dimension. Now for the critical work underway. The portfolio remediation and transformation work, what we’re calling One InnovAge, has three key dimensions and I will use these as a framework to provide progress updates on this and future calls. They include: first, creating operational excellence as a provider by formalizing a repeatable blueprint to deliver personalized, integrated, yet distributed care in our centers virtually and in home; second, expanding our payer capabilities to ensure we’re effectively managing the total cost and quality of care, and that our revenue accurately reflects the acuity of the populations we serve; third, strengthening enterprise functions to enable our centers to reach their full potential through robust talent management, data analytics, sales and marketing, and government relations, underpinned by a uniform way of working and success metrics. Let me walk through each of these dimensions in more detail to give you a flavor of our key areas of focus and where we are currently. First, operational excellence as a provider. First and foremost, our primary focus continues to be addressing the deficiencies identified in recent audits in as rapid a time line as possible, and returning to growth in the mid to long term. The audit results have found gaps in our performance when compared against regulatory and our own expectations. In February, I categorized the nature of our compliance deficiencies into two broad buckets: care coordination and care documentation. Over the past 90 days, my understanding of each identified deficiency, the root causes and the critical capabilities needed to become compliant, have come into a much sharper focus. To elaborate, I’ve established eight initiatives that are intended to support the remediation of audit identified deficiencies, and earn back the trust of all stakeholders: one, filling critical personnel gaps at each of the centers, it all begins here; two, standardizing the process of our interdisciplinary care teams who plan and coordinate and deliver care; three, strengthening our home care network and reliability; four, improving timeliness of scheduling and coordinating care with providers outside the centers; five, improving our telephonic channel response times and closing critical communication loops; six, improving the efficiency and reliability of transportation for our participants; seven, standardizing our wound care program across the enterprise; and eight, reducing documentation outside of the EMR. Importantly, we have been proactive in the broad implementation of these consistent operational processes at each of our centers to ensure identified deficiencies are resolved and do not recur anywhere in our portfolio. We are making solid progress on all fronts and expect to complete our short-term objectives for these initiatives by calendar year end. Second, dimension too is expanding our payer capabilities. As mentioned earlier, PACE is a unique value-based risk-bearing model that requires excellence at both provider and payer competencies to serve this population at scale. Historically, PACE programs are primarily focused on care delivery side of the equation, and the same is true at InnovAge. This creates an opportunity to better manage total cost of care, and ensure we receive appropriate payment for services provided. The core payer capabilities I am describing include effectively managing provider networks and contracting to optimizing the costs, leveraging evidence-based guidelines and rigorously optimizing quality, value and utilization of services, ensuring we are paying external providers appropriately for bill procedures, and accurately matching risk-based payments with the acuity level of our participants, to name a few. To be clear, these capabilities exist within InnovAge today, but the scorecard is mixed. We compare well to other PACE programs on utilization measures like ER visits, admits, conversion of inpatient days to observation days, and we’re proud of this. But we’re also looking to benchmark ourselves on quality, outcomes and cost against all other best-in-class value-based providers serving frail senior populations on a fully capitated basis. Given its importance, we’re actively starting down the path of building a comprehensive payer capability roadmap and an actionable portfolio of quick hit and longer term initiatives with help from a specialized consulting partner. This outside-in perspective is important and it will take time to size, implement and foray benefits to fully materialize in our P&L. We will provide further updates on future calls as we continue to get our arms around the range of incremental value at stake and what’s needed to begin to capture it. Three, building the right enabling enterprise capabilities to empower the centers, lasting gains from remediation and transformation efforts will hinge on the development of a handful of critical enabling capabilities at the enterprise level. Starting with talent. Focusing on talent will be core to everything we do as our success starts and ends with having the best people in every job. Therefore, we’re building a robust talent engine to attract, retain, develop and recognize our people. To that end, we have made progress this quarter in adding key executives to our team to help broaden and deepen our leadership across several important areas. Enterprise-wide, we’ve added approximately 100 net new FTEs despite the tight labor market for healthcare talent. As is also natural at times of major change, we have had a few leaders who have left our team or will be leaving imminently. As referenced in the press release, Dr. Melissa Welch, InnovAge’s Chief Medical Officer, has announced her intent to pursue opportunities outside the organization. To ensure a smooth transition, Dr. Welch has agreed to remain in her current role through mid-June. Dr. Ann Wells, our current Chief Medical Officer for Population, Health and Quality, will assume the role of interim CMO upon Melissa’s departure, while the company completes its external and internal search for a permanent replacement. I want to personally thank Melissa for her numerous contributions to the organization, especially during COVID, and meaningful impact on our participants. I wish her the very best in her future endeavors, and would also like to thank Ann for assuming this critically important interim role. Next, technology. With people as our true north, our initial focus is on technology to make our people more productive and efficient. Right now, we’re focused on the basics: reducing fragmentation across systems and tools, infusing more data and insights into decision-making, and automating manual tasks. Marketing and enrollment. Once the audit identified deficiencies have been fully remediated and our operational processes are all in place at all centers, it’s imperative to our mission to continue to serve more PACE eligible participants. I’m confident our transformative efforts on this front will position us well to increase our center level organic growth rates in a post-sanction environment. Government and public affairs. I spent considerable time engaging with our regulatory partners to ensure they have full access to me, have regular opportunities to provide input in direction and can readily observe the results of the changes we are making. We recognize that some of our state partners were disappointed in us, and it’s our job to restore their trust and confidence. We’re doing this through a commitment to transparency, responsiveness and accountability and I am highly encouraged by the collaboration and positive feedback from CMS and our state partners. Culture, communication and organizational alignment. Chief among building an aligned and engaged workforce is cultivating the One InnovAge mindset and organizational culture, providing regular transparent and inspiring employee communications, establishing easy-to-understand organizational priority pillars, and connecting everything to a balanced scorecard to measure collective success as an organization. Cost structure. Lastly, as you would expect, we have identified opportunities to better align our cost structure to support the self-funding, where possible, of new investments. Investing more in field-based functions and running more efficiently in some corporate areas, for example. We are looking very closely at non-center level cost, non-labor and overhead cost, procurement contracts and capital assets to ensure we are operating at optimum efficiency. We believe there is opportunity, and every bucket is under scrutiny. To this end, we have already begun to streamline our change in reporting structures, creating clear lines of accountability across the P&L, which we expect will result in faster decision-making, greater focus, accountability and operating together as One InnovAge. I’ll now provide a brief regulatory status by market. In Sacramento, we continue to execute against the corrective action plan that was accepted in January. Since February, we’ve progressed significantly in our performance against the key criteria that CMS and DHCS will use to measure our progress against the audit findings. In Colorado, we are pleased to share that CMS accepted our corrective action plan in late April. We’re responding to the state of Colorado’s remaining questions on our submitted CAP, and we believe that our plan will be soon accepted. If approved, the activities are likely to follow a similar timeline to that of Sacramento, which began 3 months prior. In New Mexico, we received formal feedback from CMS in March that based on the results of the audit, which are consistent with those of Sacramento and Colorado we have been referred to enforcement. We’re currently awaiting feedback from CMS on next steps. In San Bernardino, we received an audit request from CMS and DHCS in February, and received preliminary findings in mid-April. The high-level findings are consistent with the deficiency cited in Sacramento, Colorado and New Mexico, and we’re working with both agencies on the specific timing of a corrective action plan. At this time, our Pennsylvania and Virginia centers have not received request for audits. However, we are proactively enacting enhanced compliance ahead of any formal request. In Florida, we’ve committed to CMS and AHCA that will proactively pause the remaining steps in the expansion process to allow us to focus exclusively on resolving our active audit issues, and cannot yet determine if a launch in fiscal year ‘23 remains viable. We are still not able to estimate when existing or forthcoming sanctions will be lifted, or the timing of future audits in Pennsylvania and Virginia. Our regulators will determine the timing of audits and sanction release once we’ve met all the criteria. As mentioned earlier, we’re in regular communication with our agency partners around the status of existing audits and how best to collaborate with respect to our other centers. In the meantime, we plan to focus on proactively remediating deficiencies across our entire portfolio. With that, I will transition to a review of the third quarter business results and drivers. We reported revenue of $177.4 million, which represents a sequential increase of 1.1% compared to last quarter. We ended the quarter serving approximately 6,800 participants, which represents a sequential decline of 3.5% compared to last quarter. We also reported a center level contribution margin of $28 million and a corresponding center level contribution margin ratio of 15.8%, which represents a decrease of 32% sequentially when compared to second quarter fiscal year 2022 and center level contribution margin of $41.4 million. We spent the last month analyzing the attribution of these results, and I will summarize the core drivers as: net census decline resulting from the sanctions; elevated external medical expenses which were primarily driven by the lingering impacts of the Omicron variant, specifically Omicron increased the utilization and unit cost of inpatient days and ER visits; and non-community respite stays and skilled nursing and assisted living facilities relative to historical averages. We are also seeing the impacts of higher acuity. Given the frail nature of our population, average acuity rises with the passage of time. The risk pool of our population has become more acute, as we have not replenished our population mix with newer, lower acuity participants. Higher general and administrative expenses as a result of investments we’re making on the provider side to accelerate the remediation of the identified audit deficiencies, and one-time costs associated with third parties and restructuring. These results are disappointing and frankly below our expectations. As a leadership team, we understand that we must do better. We are set up to benefit from scale, and this will be a great attribute for InnovAge in the future. However, performance this quarter highlights the financial impact of not growing our participant base, coupled with elevated direct and indirect costs that are largely attributable to COVID. Given what we have observed in the quarter along with larger initiatives in-flight, I wanted to spend a minute on our margin profile. In the near term, we are making investments across the eight provider initiatives referenced earlier to strengthen the platform as rapidly as possible to ensure our centers have the people and tools needed to be compliant and successful. Somewhat offsetting these additional expenses in the near term will be the efforts across our G&A reductions. As transparency is my ongoing commitment to you, I want to acknowledge that I expect there to be net margin compression in the near term until we close critical gaps and strengthen the foundation. What I can say is that the company is putting in place strong SG&A controls and the discipline to leverage our fixed cost base. It remains too early to forecast exactly how these will net out in the long term, particularly since we have not yet quantified the potential long-term impact of the payer initiatives, but we will continue to hold ourselves accountable to an attractive long-term margin profile. I began the call noting that our priorities encompass both near-term operational execution and mid to long-term capability development. So to summarize, job one in my commitment to our participants, employees, government partners and shareholders continues to be doing everything necessary to be released from sanctions, and to avoid future sanctions by proactively fortifying our foundational operational processes on an organization-wide basis. This work is largely about becoming a better provider, and we’re making measurable progress on this objective. Second, the opportunities to manage the total cost of care by becoming a more sophisticated payer will be a mid to long-term objective. Further, as an additional part of this horizon, we’re committed to building the tools, technology and cultural elements needed for a highly engaged workforce. While our confidence increases by the day, it’s important to acknowledge that we have a long way to go. As I said before, with the right leadership, focus, execution and ownership and accountability, we will build a stronger InnovAge. I’ve been fortunate to have been associated with organizations that have successfully navigated periods like this, and the businesses emerge stronger. There is nothing more important than ensuring we are consistently delivering outstanding care to our participants. What’s more, I believe an unwavering focus on people, service and quality, will lead us to the performance we aspire to, and earn us the right to serve more deserving PACE participants across the country. Again, I want to sincerely thank you, our regulatory partners and our employees, for your support. And with that, I’ll hand it over to Barb.
Barbara Gutierrez: Thank you, Patrick. I will provide some highlights from our third quarter fiscal year 2022 performance. Given the impact of Omicron during the period, in some cases I will refer to sequential comparison to our second quarter of fiscal 2022 in order to provide a more meaningful view of our performance. As of March 31, 2022, we served approximately 6,800 participants across 18 sectors. Compared to the prior year period, this represents an ending census increase of 2.1%. Compared to the second quarter of fiscal year 2022, this is a decrease of 3.5%. We reported approximately 20,630 member months for the third quarter, a 3.4% increase over the prior year and a decrease of 2.6% over the second quarter of fiscal 2022. Sequentially, the enrollment freeze in Colorado had the greatest impact on member months and census in the third quarter. Additionally, as we indicated in our second quarter remarks, towards the end of the second quarter and continuing into the third, we experienced an increase in total deaths. While not uncommon during the winter months, total deaths coupled with added enrollment growth pressure as a result of the Omicron surge also impacted our census growth. The Omicron surge affected our ability to interact directly with potential new participants, and cause delays and lengthening of the enrollment process. Revenue in the third quarter of fiscal year 2022 increased to $177.4 million or approximately 13.5% compared to the third quarter of fiscal year 2021. Year-over-year growth drivers include an increase in census, the calendar year increase in Medicare rates effective January 1, 2022, and an increase in Medicaid rates which include temporary rate increases from the American Rescue Plan Act or ARPA in Virginia and Colorado. Specific to Colorado, we recorded a true-up of ARPA funds for the first half of fiscal year 2022 in the third quarter, and we are still in discussions with other states regarding further ARPA rate increases. As we mentioned last quarter, we received a mid-single-digit rate decrease in our California Medicaid rate effective January 1, 2022. The decrease is the result of California’s experience-based rate-setting methodology and the inclusion of our calendar year 2020 experience, which is understated due to the shutdowns during the pandemic. While we cannot predict what our rates will be next year, we have encountered higher utilization in calendar year 2021 as our centers reopened, which will be factored into the rate-setting methodology for calendar year 2023. External provider costs in the third quarter were $103.3 million, a 37% increase compared to the third quarter of fiscal year 2021. While some of this variance is due to census growth, the main drivers of the increase are: one, an increase in inpatient and medical respite utilization and acuity as a result of the Omicron surge; two, increased housing utilization; and three, increased housing rates as mandated by certain states, including an ARPA funded public policy adjustment in Colorado that increased assisted living rates by more than 30% effective January 1, 2022. This assisted living rate increase in Colorado was not offset by a direct increase to our reimbursement rates. Additionally, while outpatient and specialist utilization has leveled off, utilization was higher compared to the prior year as a result of the pent-up demand of healthcare services that were delayed during the pandemic. Inpatient utilization has improved in the back half of the quarter following the Omicron surge. However, the number of and cost per COVID admit has increased year-over-year. Additionally, participants that have recovered from COVID have a higher acuity due to the inherent frailty of our population. External provider costs in the third quarter of fiscal 2022 increased by 13.4% compared to the second quarter. The sequential quarter increase is driven by the Omicron surge and its impact on inpatient and medical respite utilization and cost, and the increase in Colorado assisted living facility rates effective January 1, 2022. We are in discussions with the state of Colorado regarding fiscal year 2023 rates. Our cost of care, excluding depreciation and amortization, was $46.1 million for the third quarter, a 16.5% increase over the third quarter of fiscal year 2021, driven by an increase in census and an increase in the overall cost per participant. The 12.7% per member per month increase is primarily due to: one, higher wage rates associated with a competitive labor market; two, additional labor cost associated with ongoing audit remediation and compliance; three, greater operational costs due to the reopening of our centers that were closed during the pandemic; and four, pre-opening losses associated with de novo locations. Cost of care increased by 7.4% over the second quarter of fiscal 2022 primarily due to additional labor costs associated with ongoing audit remediation and compliance, one-time cost of approximately $400,000 associated with organizational redesign in increased headcount as we make significant progress in filling vacancies, and costs associated with the annual reset of employee benefits and taxes. Center level contribution margin, which we define as total revenue less external provider costs and cost of care, excluding depreciation and amortization, was $28.0 million for the third quarter compared to $41.4 million in the third quarter of fiscal 2021, and $41.4 million in the previous quarter of fiscal 2022. As a percentage of revenue, center level contribution margin for the quarter was 15.8% compared to 26.5% in the third quarter of fiscal 2021, and 23.6% in the previous quarter of fiscal 2022. The primary drivers of the year-over-year decline in center level contribution margin as a percent of revenue are: one, the impact of the Omicron surge on inpatient and medical respite utilization and cost; two, increased housing utilization; three, state mandated housing rate increases; and four, medical cost normalization. We also experienced an increase in cost of care due to wage pressures and additional staffing related to compliance and remediation efforts, and other occupancy-related expenses. Sales and marketing expense for the third quarter was $6.1 million, an increase of approximately $600,000 compared to the third quarter of fiscal 2021, and was primarily due to increased headcount over the prior year, coupled with one-time cost related to organizational realignment, partially offset by a reduction in marketing spend associated with the ongoing enrollment sanctions. Sales and marketing expense decreased sequentially from the second quarter of fiscal year 2022 by approximately $500,000. This decline was primarily due to a reduction in marketing spend associated with the ongoing enrollment sanctions, partially offset by one-time cost related to organizational realignment. Corporate, general and administrative expense for the third quarter was $24.7 million, an increase of $6.1 million compared to the third quarter of fiscal 2021. The increase was primarily due to an increase in headcount, increased costs associated with being a publicly traded company, and one-time compliance-related cost, and costs associated with organizational realignment of approximately $1.4 million. Net loss for the third quarter was $3.2 million compared to a net loss of $10.9 million in the third quarter of fiscal 2021. We reported a net loss per share for the fiscal third quarter of negative $0.02 on both a basic and diluted basis. Our average fully diluted share count was 135,516,608 shares for the third quarter. Adjusted EBITDA, which we calculate by adding interest, taxes, depreciation and amortization, one-time adjustments for transaction and offering related costs and other non-recurring or exceptional costs to net income, was $1.9 million for the third quarter compared to $20.3 million in the third quarter of fiscal year 2021 and $14.8 million in the previous quarter of fiscal year 2022. Our adjusted EBITDA margin was 1.1% for the third quarter compared to 13.0% for the third quarter of fiscal year 2021, and 8.4% for the second quarter of fiscal year 2022. The quarter-over-quarter change in adjusted EBITDA and adjusted EBITDA margin is primarily a function of increased external provider costs and increased cost of care, offset by reduced marketing spend and lower corporate general and administrative expense as a result of one-time cost associated with leadership changes in the second quarter. We do not add back any losses incurred in connection with our de novo centers in the calculation of adjusted EBITDA. De novo center losses, which we define as net losses related to pre-opening and start-up ramp through the first 24 months of de novo operations, were $1.0 million for the third quarter. This includes expenses for centers in Downey, California; Louisville, Kentucky; and our Tampa and Orlando centers in Florida. Per Patrick’s remarks with respect to Florida, we have committed to CMS and the Agency for Health Care Administration, or AHCA, that we will proactively pause the remaining steps in the expansion process to allow us to focus exclusively on resolving our active audit issues, and cannot yet determine if a launch in fiscal year 2023 remains liable. Turning to our balance sheet. We ended the quarter with $199.5 million in cash and cash equivalents, and had $88 million in total debt on the balance sheet, representing debt under our senior secured term loan plus capital leases and other commitments. For the third quarter ended March 31, 2022, we recorded negative cash flow from operations of $7.5 million, and we had $9.9 million of capital expenditures. Free cash flow, defined as cash from operations less capital expenditures, was negative $17.4 million for the quarter and positive $2.5 million for the 9-month period ended March 31, 2022. In late December, we announced we were withdrawing guidance following the sanctions we received in Colorado, and subsequent enrollment freeze. At this time, we do not believe it is prudent to provide new or updated guidance due to the ongoing audits and continuing remediation efforts. As Patrick indicated, we plan to focus on proactively remediating deficiencies across all of our portfolio. We can, however, provide some insight into the trends we are seeing today, and the impact to our business in several key areas. Starting with revenue. We have already begun to streamline our teams and reporting structure, realign the sales and marketing functions, and add new leadership. Although the recent COVID surge lengthened the time it took us to enroll participants into the program due to disruption from potential or actual exposure for employees and prospective participants in the second and third quarters, we are beginning to see enrollment levels in our non-sanctioned centers return to pre-Omicron levels and our mortality rate is returning to average levels. From a medical expense perspective, we expect elevated external provider costs due to Omicron to continue in the near-term. Specifically, we expect inpatient and specialty costs and medical respite costs at skilled nursing facilities to remain elevated due to the increased risk of severe illness from existing underlying conditions when contracting COVID. In some of our markets, participants are returning to assisted living facilities at pre-COVID levels and above. Finally from a cost of care perspective, we continue to experience the tight labor market as we manage our employee base to meet the needs of our participants. As a reminder, we included market wage adjustments when we provided our initial guidance last summer, and we continue to closely monitor wages to ensure we remain competitive. We have seen elevated wage rates in certain critical positions beginning late in the second quarter, and we expect additional labor costs associated with the ongoing audit remediation and compliance, to continue in the near-term. As Patrick highlighted in his remarks, we are at an inflection point for the company as we emerge from the pandemic and address the challenges of the current sanctions. However, I believe that the transformation we are undertaking will solidify our foundation to ensure that we are focused on people, service and quality, and that we are well positioned for scalable and sustainable growth for the long-term. Operator, that concludes our prepared remarks. Please open the call for questions.
Operator: Thank you. And our first question comes from Jeff Garro from Piper Sandler. Your line is now open.
Jeff Garro: Yes. Good afternoon and thanks for taking the questions. I guess I’ll start on the cost side of things. You cited five items pressuring center level contribution margins. Could you help us categorize which ones of those you feel are near-term and which ones might persist for some time?
Patrick Blair: Thank you for the question, Jeff. I’ll get it started. Then I’ll hand it over to Barb. Yes. First thing I’d point out is the COVID-related cost, clearly one where we saw a spike in January I think with roughly half the population that contracted COVID in January. And those admissions were up for us as well as some of the increases in utilization of skilled nursing days and some of the ancillary costs surrounding that. I am going to let Barb go a little bit deeper into the drivers.
Barbara Gutierrez: Yes. Thanks for the questions. So as Patrick said, certainly in the third quarter, a significant portion of our higher costs as it relates to external provider costs, were related to the Omicron surge. So of those excess costs, about 50% of those excess costs in some way, form or fashion were attributable to that surge, whether that was inpatient, medical respite, ongoing specialty care. And while we have seen the – seen COVID abate going into the fourth quarter, we expect those costs to come down in the short-term but not completely go away. As you know, our participants are inherently frail and have a number of comorbidities, and so what we are experiencing is a long tail, if you will, as it relates to those external provider costs for those participants. So the good news is we have seen the COVID rate decrease towards the end of the third quarter and into the fourth quarter. But again, those costs won’t go to zero in the fourth quarter. There is a tail associated with that. Secondly, the wage increases were a factor as well. And like I think, everyone in the healthcare industry, we’re seeing a lot of pressure and a tight labor market, and we’ve done a number of increases related to our staff as well as trying to close the gap on some of our staffing. So that will continue as well. We did have some more one-time costs in nature related to organizational realignment that will not reoccur in the fourth quarter or in the near-term. And then just some of the overall other costs, we foresee sales and marketing are nearly flat quarter-over-quarter, and that really results from the sanctions. We see that being pretty constant. And our G&A are really investments in transformational activities as well as some compliance activities. And we will see that continue a bit to the fourth quarter as well. I think I answered them all.
Jeff Garro: Excellent. Yes. Great. All super helpful. Maybe to follow-up a little bit, focusing on the cost of care line and just trying to think about – I think great in the tight labor market, you’re able to add 100 net new FTEs. So I’m curious what roles you were able to hire people for? And just trying to parse out how much of the increased cost of care, despite where census has trended, is related to wage pressures, and how much is related to all of those efforts that Patrick discussed around you becoming a stronger provider and delivering a stronger value for your members?
Barbara Gutierrez: It’s a bit of each of those items. We have seen in terms of the wage pressures in the high single digits compared to a year ago, and I think that’s been consistent with what we reported on other calls, that kind of high single digits. And so that is definitely a factor. And then adding the new participants – sorry, the new employees is another factor. We are continuing to work on that and strengthening our recruiting. So I think it’s a bit of both.
Patrick Blair: Yes, I might just add on and just reinforce that we’ve identified a core set of physicians that we really put into the critical hiring bucket. They include nurses and CNAs, personal care workers in various therapies and social workers. And if memory serves me, the last couple of months or at least in the last quarter, we’ve had roughly about 200 or so of those that we’ve sort of carried as a vacancy. And I think we’ve made progress on at least 30% of those just in the last 6 weeks to 2 months. So we are making – we’ve got a very focused effort on these critical positions and are really, I think, doing a great job attracting people in the company and attracting people to the mission and purpose of the business. And so we’re starting to see some improvement in the recruitment of these critical roles.
Jeff Garro: Good to hear. Thanks for taking the questions, again.
Operator: Thank you. And our next question comes from Sarah James from Barclays. Your line is now open.
Sarah James: Thank you. I wanted to go back to the comment that Barb made earlier about the ARPA regulatory change in Colorado. Just want to confirm that was 30% cost increase with no rate offset. And then I was going through the last couple of calls. I guess you guys flagged a 5.3% rate increase for Colorado and Virginia in November related to housing costs. So, I just want to understand if we look at this as like a 2-year run rate, what exactly is going on with housing costs? And how should we think about that as a percent of your total cost structure?
Barbara Gutierrez: Thanks, Sarah. Clarifying the Colorado ARPA sorry, I paused there because there was a little bit of an echo. Let me just clarify that. So, I think in the remarks, I said there was no direct reimbursement. There is definitely some indirect reimbursement. And so we received some ARPA funds, we received as a matter of public policy adjustment related to ARPA. So, we have received a couple of increases there. But the structure of it is not a direct one-for-one reimbursement. And the philosophy there is, we are being reimbursed through some of the ARPA and inherently through our rate structure. So, we are still in discussions with the State of Colorado as it relates to FY ‘23 rates. And you did understand correctly, it was a very significant increase for Alps . It was over 30%. And a significant portion of our participants in Colorado actually live in Alps, which is why it’s pretty significant for us. The other increases we mentioned in the previous quarters. We also received from Virginia about a 2.5% increase related to ARPA. And in some part, that covers some of that housing increase. We do not have the same level of housing in Virginia. So, it’s not the same issue from a reimbursement perspective.
Sarah James: Can you size housing costs for us? Like what percentage of your cost of care line is it, or how should we think about factoring in some of these increases into the model?
Barbara Gutierrez: Yes. So, probably not off the top of my head, but again, think about over a third of our participants in Colorado reside in Alps. And I think that’s the way to think about it.
Sarah James: Okay. Thank you.
Operator: Thank you. And our next question comes from Jamie Perse from Goldman Sachs. Your line is now open.
Jamie Perse: Hey, good afternoon Patrick and Barbara. Patrick, maybe to just start with you on the eight initiatives you outlined. Obviously, a lot going on to remediate the audits and just improve quality of care overall. How would you kind of characterize where you are in terms of establishing these initiatives, the timing that we should be thinking about for some of the different initiatives, where the easier lifts are versus some of the more challenging longer term lifts? Just a little bit more color on how we should think about, I don’t know, phasing or implementation of these key initiatives going forward?
Patrick Blair: Sure. Thanks for the question. I would start by saying that we are making progress on all eight of these. I mean clearly, there is different impact and value for all of them, but we are simultaneously executing sort of full speed ahead on all eight. If I think about where it all starts, clearly the critical personnel gaps is the foundation for everything. And as I mentioned, we have identified the critical personnel that are making significant progress. I think I said 30% of some of what’s been sort of in our vacancy run rate we have been able to fill. When I think in terms of those that I think are having the greatest near-term impact. Two I would call out would be, one, scheduling care with outside providers. We have made a lot of progress on building our tools and our processes to ensure that our people are being scheduled, and external providers, as quickly as possible and as timely as possible. So, that is an area where getting people to their provider really starts the care delivery model for us. And so that’s critically important. We are making great progress. Our – the telephonic channel with our phones just being available to our participants and their caregivers and make sure that every call that comes into the center, we are returning that call on a timely basis and then we are documenting the needs of the population. I think that’s an area where we are making really good progress on. One of the areas, I think is going to have a longer tail on it, it probably won’t surprise you, is sort of strengthening our home care network and the reliability. This really ties back to the people constraint, is finding the right number and the right skill set within the personal care worker is really important to us, and it’s an important part of what we need to do to keep people living independently in their homes. And I think that’s an example of one of our initiatives that’s going to take longer. But for the most part, I would say we are expecting all, like let’s call it, Phase 1 of all eight of these to be in very solid footing. And by Phase 1, I mean we will have addressed the compliance issues. So, if I had to break it up into sort of Phase 1, is really about making the changes necessary to address the audit findings and to remediate those issues everywhere they exist. I think we will be complete with that by the end of this year. Then the next phase is really more transformational in nature, and it’s really taking each of these areas to the next level of efficiency using technology, using more automated business processes, etcetera. So, I think that that’s probably more on the 18-month to 2-year timeframe to take things to the sort of the next level, but certainly remediating the deficiencies by the end of this year across all eight initiatives is an expectation we have.
Jamie Perse: Okay. Thanks. That’s really helpful. I wanted to follow-up just on the status of the Sacramento facility. I know the cap is in place there and your – I guess the question is, what’s the level of oversight right now by auditors? Are they monitoring you on a kind of day-to-day basis, or what does that look like? And is it still right to think that there will be a phase you go through where they are moderating pretty closely and then they let you operate more independently for a while? And then beyond that is when the enrollment freeze might be lifted. And then if I could just sneak in one more, just if Virginia and Pennsylvania, what the status of conversations is like there, what their familiarity is with your other audits, and how you kind of characterize the risk of changes you are seeing right there? Thanks.
Patrick Blair: Sure. I appreciate the question. Starting with Sacramento, I think you articulated sort of the audit cycle well. There is always a great deal of engagement with CMS in the state. But you are correct in that we are, I will say, at the precipice of where CMS’s level of monitoring is done much more through reporting oversight. So, there are specific measures, which – nine of them that we are being measured against in Sacramento, and we are reporting that information to CMS sometimes in a biweekly or monthly basis. And we are very pleased with the progress we are making. And if we can keep that progress up, you are correct in that the next step would be for CMS to give us some time to make sure those changes and those results are sticking, and then come back in and do an audit again, a quick audit, to see where we are to make sure the changes are stuck. And it’s our understanding if that all goes well, then we are positioning ourselves for sanctions to be lifted. But of course, that’s always in the discretion of CMS. So, I would just say, really pleased with the team’s progress in Sacramento. As it relates to Virginia and Pennsylvania, how I would describe that is, our close work with CMS across multiple markets now, and the themes they are seeing across our markets, and the progress we are making across addressing those deficiencies, I believe CMS is acknowledging that we are making good progress. We are focused on the right issues. We are remediating things timely. We have got a strong communication, open communication channels between us. And as a result, we have not received any notice from CMS or the State of Virginia or Pennsylvania on any planned audits. Of course, they can happen at any time, but we always receive a notice in advance, and we have not received anything yet. So, I think our belief is, we are working closely with CMS, and they are very aware of our themes and our progress. And we are applying the learning to all the markets. So, anything we learn in Sacramento, New Mexico, Colorado, we are bringing those same things to Virginia and Pennsylvania proactively.
Jamie Perse: Okay. Understood. Thanks for the update.
Operator: Thank you. And our next question comes from Matt Larew with William Blair. Your line is now open.
Matt Larew: Hi. Thanks. Good afternoon. Barb, I wanted to follow-up on your comments. Obviously, you are not giving guidance, but you did kind of describe what you are seeing in terms of current trends with enrollment at non-sanction centers returning. I do want to clarify, though, with about two-thirds of your census following into sort of Colorado and New Mexico and the California centers, and 2% attrition per month, I mean we should be expecting sequential declines in census for some period of time here. Is that fair to say? I just want to make sure that we are not misreading the commentary about enrollment returning in the non-fiction centers into something that’s not going out company-wide?
Barbara Gutierrez: Yes. So, thanks for the question, Matt. The only clarification I would make is that the centers on sanction are Sacramento – currently on sanctions, Sacramento and the Colorado centers. So, I know in your question there, you included other California centers in New Mexico which are not currently on sanction. And then in addition to that, there is Virginia and Pennsylvania.
Matt Larew: But I guess just to clarify, your sort of internal expectation given that they are following the path of Sacramento and Colorado is that they will eventually be on showing you out there a similar process, or sort of what’s in your operating model for that?
Barbara Gutierrez: That’s not what we are assuming, especially in the comments that I gave just a bit ago. So, the comment is, again, on the non-sanctioned centers.
Patrick Blair: Yes, this is Patrick. I think I might just punctuate the point in terms of internal expectations. As I have said before, this is entirely in the discretion of our regulators. But I think internally, we recognize that both CMS and states have a broad range of options available to them when it comes to enforcement of audit deficiencies. And a corrective action plan with an enrollment freeze is just one of the several options that CMS or state has available to them. So, I think as we think about each market, we think about it on its own merits and we think about the latitude that CMS has, and that each market that while the themes may be similar, the actual severity and frequency that – of the deficiencies could vary by market and could lead to very different outcomes. And so that’s sort of how we are thinking about it. And then I think as we think more broadly to markets that are under sanction in addition, we also think about the proactive nature of our work to address audit deficiencies that maybe all hasn’t occurred yet, but we are already at that location, looking at the opportunities, looking at what we have learned from the other markets and seeing if there is an opportunity to get ahead of it. So, I would just add that color to Barb’s comments.
Matt Larew: Okay. That’s really helpful, Patrick. And then, Patrick, maybe just sticking with some additional commentary, you referenced some of the corrective actions that you have taken. You also said you identified sort of root cause for all of them. Curious, could you share with us what, in your view, the root cause a lot of these issues were? And the reason I am asking is, I think it would be helpful to understand if it was deficiencies, and people or processes or technologies in order to help frame what the type of investments are that are going to be required to really solve not a surface level and a root cause across the organization?
Patrick Blair: Sure. I would happy to. I would first say that for any deficiency, I always think of it, we always think of it in terms of people, process and technology. And although business process automation or introducing new technology can be expensive, I think what we are finding in more cases than that is that, simple technological advancements or automation can make a big difference in the deficiencies we need to close. It very much is about the fundamentals of having the right people, having solid business processes and policies and procedures that are followed, and having tools that help our employees be efficient and enable them in the work that they are doing. In terms of the root causes, just working from sort of top of mind here, it’s things like ensuring our medical records are documented with all the required data elements, much more people and policy, procedure focused, ensuring that our care plans are complete and kept timely, a lot about training and people in process. The heart of our business is this multifaceted interdisciplinary care team at the center level, making sure that team is each day capturing input from all other team members. Whenever that information is available, it is been documented in the EMR or in other tools that feed the EMR. There, you are getting to get it, training of people, process and tools to capture data, making sure that our service orders are being scheduled on a timely basis, making sure that when a participant or a caregiver requests a service that we are identifying that appropriately, and we are documenting it. So, see, you can get a feel for it. Those would be the things that I would say are root causes of our compliance deficiencies. They are the fundamentals of basic blocking and tackling. And the eight initiatives that I articulated, I have a great deal of confidence that if we execute flawlessly on those eight initiatives by the end of the year, they substantially account for, and it will address all of our audit deficiencies. And then next year and the year after, we begin thinking about how do we take those to the next level and become more efficient, more automated, more controlled. Hope that’s helpful.
Matt Larew: That’s really helpful, Patrick. Thanks for all the commentary.
Operator: Thank you. And our last question comes from Andrew Lothian from JPMorgan. Your line is now open.
Andrew Lothian: Hi. This is Andrew on for Lisa Gill. I just wanted to go back to your comments on patient acuity going up over time. So, in light of the freezes, I was wondering how you are thinking about driving growth in existing markets, given the compressed marketing spend. The limited growth would probably seem to indicate that cost of care would remain a bit elevated relative to historical patterns. So I was wondering if you had any incremental color on that? Thank you.
Patrick Blair: Well, I can share a little bit on the sales side and then if someone else on the team wants to weigh in. As it relates to our sales and marketing costs, we are very cognizant of our ratios for sales and marketing, and we are going to be very – we have been very smart about how much of a cost structure we maintained given that we have markets under sanction. And we have taken steps already to reduce costs in the markets today. And then on the marketing side, because these are highly variable costs, we have already taken costs out of the marketing side of the equations, which is going to allow us to move more quickly. We are also deploying sales resources in sanction markets to, let’s call it, participant experience and retention efforts in both sanctioned markets and non-sanctioned markets. And that’s relevant because we are very much focused on that portion of our disenrollment rate that we can control, and we are using those resources from a participant experience perspective to help with some of that disenrollment. And I think as Barb mentioned, we are starting to see some of that play through in the current period. As it relates to the risk pool, I am going to ask Melissa to say a little bit about that. But you are exactly right that we have had quite a few participants contract COVID as they leave the hospital. Many of them were no longer able to be at home and reside in higher cost settings. And especially in a market like Colorado, where it’s one of our largest markets where we have the highest degree of sort of Alps utilization, we clearly have a challenge of not bringing in enough new lower acuity participants into the pool. And that’s something that we are very focused on, and looking for every opportunity to manage that population as well as we can. But let me ask Melissa to weigh in too.
Melissa Welch: Hi Andrew. Yes, I think Patrick captured the cause of the increased acuity. Certainly in this last quarter, COVID had a huge impact on our participants’ acuity for the quarter. Mix is important to us. So, it is going to be important for us to continue to bring in newer, ideally less sicker participants on some aspects to help dilute that. But our real focus is going to be on being able to predict the acuity. And some of the technology investments that were identified by Patrick earlier will help us to do that. Our new EMR technology is also going to help us to do that. And I think that, that ability to really predict our cohort of acuity and manage it upfront more accurately, is going to be a significant value for us in the long-term.
Patrick Blair: Yes. I might just add one last thought to that. And naturally, we have a number of initiatives that run on a daily basis where we are focused on things like the short stay and skilled nursing facility and the length of stay, as Melissa mentioned, a variety of side of care strategies that we have in place to try to address the utilization, a number of things around the use of ER and trying to reduce the unnecessary use of ER. And all these things, I think also play to highlight – really highlight the importance of a more sophisticated payer strategy and capabilities going forward, which I mentioned in my opening remarks.
Andrew Lothian: Thanks for the color.
Operator: Thank you. And this concludes today’s conference call. Thank you for participating. You may now disconnect.
